Jaguar Health, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. Although the request refers to 2022 Q4, this filing reports annual results; it does not provide a clear stand-alone fourth-quarter income statement or cash flow.
Business context
Jaguar is a commercial-stage pharmaceutical company focused on plant-derived gastrointestinal medicines. Its principal marketed human product is Mytesi (crofelemer), approved for noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy. Canalevia-CA1 is conditionally FDA-approved for chemotherapy-induced diarrhea in dogs. Most development activity centers on crofelemer, including a Phase 3 trial for cancer therapy-related diarrhea and rare-disease programs in short bowel syndrome and congenital diarrheal disorders. NP-300 is an earlier-stage candidate for infectious diarrhea, including cholera.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Net product revenue | $12.0 million | $4.3 million |
| Gross product sales | $15.0 million | $15.7 million |
| Cost of product revenue | $2.0 million | $2.3 million |
| Gross profit and gross margin, calculated from reported figures | $9.9 million; 83.1% | $2.0 million; 46.2% |
| Operating expenses | $46.4 million | $45.0 million |
| Loss from operations | $(34.4) million | $(40.7) million |
| Net loss | $(48.4) million | $(52.6) million |
| Cash used in operating activities | $(33.1) million | $(35.0) million |
| Cash used in investing activities | $(1.7) million | $(0.01) million |
| Cash provided by financing activities | $23.2 million | $43.9 million |
- Revenue growth reflects the transition to a specialty-pharmacy distribution model: net sales rose 175.8%, even though gross product sales fell 4.5%. Mytesi net revenue was $11.7 million; Canalevia contributed $167,000 and animal-health products contributed $48,000.
- Cash declined to $5.5 million from $17.1 million. At year-end, current assets were $22.3 million versus current liabilities of $30.3 million; total liabilities were $48.8 million and stockholders’ deficit was $1.4 million.
- Notes payable, net of unamortized discounts and issuance costs, totaled $33.6 million, including $15.9 million current and $17.7 million noncurrent. Reported interest expense was $12.7 million, up from $8.4 million. Loss on extinguishment of debt was $2.2 million.
- Management disclosed minimum royalty payments of approximately $16.0 million in 2023, $14.6 million in 2024, $19.5 million in 2025, and $5.3 million in 2026. Contractual note maturities were reported as $15.9 million in 2023 and $23.5 million in 2024, before unamortized discounts and costs.
Material changes and notable items
- Specialty-pharmacy distribution substantially reduced sales discounts and eliminated wholesaler fees in 2022. Sales discounts fell to $1.2 million from $6.3 million, while gross Mytesi sales declined $0.9 million.
- R&D expense rose 17% to $17.6 million, primarily from clinical and manufacturing costs and additional personnel. Selling and marketing expense was broadly flat at $8.8 million; G&A increased 4.5% to $17.9 million.
- Interest expense increased by $4.3 million, principally due to royalty financing arrangements. The company also recorded a $2.2 million debt-extinguishment loss related to exchanges of royalty obligations for shares.
- Jaguar raised $20.5 million net through its at-the-market offering in 2022. After year-end, it issued another 10.1 million shares under the ATM for $17.5 million net through March 23, 2023. Shares issued to settle royalty interests also contributed to dilution.
Outlook, risks and contingencies
- Going concern: Management and the auditor state that substantial doubt exists about Jaguar’s ability to continue as a going concern. The company said it had an immediate need to raise cash and did not believe year-end cash would fund its operating plan for one year from issuance of the financial statements. The statements contain no adjustments for the outcome of this uncertainty.
- Funding and dilution: Continued losses and negative operating cash flow make additional capital necessary. Financing may not be available on acceptable terms; equity raises, debt and royalty financing may dilute shareholders or add repayment burdens.
- Clinical and regulatory execution: OnTarget enrollment was approximately 75% in February 2023, with enrollment of 256 patients targeted for completion in Q2 2023. The filing gives no assurance of trial success or future approval. Other clinical timelines are funding-dependent.
- Canalevia-CA1: Conditional approval permits sales while effectiveness evidence is collected, but requires annual renewal and eventual full approval; failure to meet requirements could end the right to market the product.
- Commercial and supply risks: Mytesi revenue is concentrated in a small number of customers; three customers represented 35% and 53% of revenue in 2022. The company also relies on two raw-material suppliers and third-party manufacturers, including a single current crofelemer API manufacturer.
- Other financing exposure: Streeterville holds a security interest in NP-300 assets. Minimum royalty obligations can exceed royalties generated by sales and may strain liquidity.
- Listing and corporate matters: Jaguar effected a 1-for-75 reverse stock split in January 2023. The filing describes Nasdaq bid-price and delisting notices; it reports that the minimum bid-price deficiency was cured in February, but also describes a subsequent delisting-related notice and intended hearing request.
- Post-year-end developments: Jaguar formed Magdalena Biosciences with Filament Health in January 2023 to explore plant-derived mental-health medicines. A separate SynWorld license agreement was mutually terminated effective January 31, 2023.
- No formal financial guidance is provided. Management’s stated near-term priorities include commercializing Mytesi and Canalevia-CA1, advancing OnTarget, and pursuing crofelemer rare-disease programs.
Most important facts for investors to verify
- Current cash, near-term cash burn, financing availability, and whether the going-concern risk has changed since the filing.
- Current debt and royalty balances, actual scheduled payments, and the terms and collateral of financing arrangements.
- Post-year-end shares outstanding and the full dilution impact of ATM sales and debt or royalty exchanges.
- OnTarget enrollment, completion timing, results, and the resources required to complete the trial and pursue any regulatory filing.
- Mytesi net sales, customer concentration, payer coverage, and the sustainability of revenue under the specialty-pharmacy model.
- Canalevia-CA1 renewal and full-approval milestones, and the company’s ability to maintain supply from its suppliers and manufacturers.